You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

CLINICAL TRIALS PROFILE FOR DESOWEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DESOWEN

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT03386032 ↗ 8-Week Atopic Dermatitis (AD) Treatment Study Completed Procter and Gamble Phase 3 2017-11-27 This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 1 of 1 entries

Clinical Trial Conditions for DESOWEN

Condition Name

10-0.100.10.20.30.40.50.60.70.80.911.1Atopic Dermatitis Eczema[disabled in preview]
Condition Name for DESOWEN
Intervention Trials
Atopic Dermatitis Eczema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

1110-0.100.10.20.30.40.50.60.70.80.911.1DermatitisEczemaDermatitis, Atopic[disabled in preview]
Condition MeSH for DESOWEN
Intervention Trials
Dermatitis 1
Eczema 1
Dermatitis, Atopic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DESOWEN

Trials by Country

+
Trials by Country for DESOWEN
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for DESOWEN
Location Trials
Tennessee 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DESOWEN

Clinical Trial Phase

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Phase 3[disabled in preview]
Clinical Trial Phase for DESOWEN
Clinical Trial Phase Trials
Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Completed[disabled in preview]
Clinical Trial Status for DESOWEN
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DESOWEN

Sponsor Name

trials000001111111Procter and Gamble[disabled in preview]
Sponsor Name for DESOWEN
Sponsor Trials
Procter and Gamble 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Industry[disabled in preview]
Sponsor Type for DESOWEN
Sponsor Trials
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

DESOWEN Market Analysis and Financial Projection

Desonide (Desowen): Clinical Trials, Market Analysis, and Projections

Introduction

Desonide, marketed under the brand name Desowen, is a non-halogenated, low-potency topical steroid widely used for the treatment of mild to moderate steroid-responsive dermatoses. This article delves into the clinical trials, market analysis, and future projections of Desonide.

Clinical Trials and Efficacy

Post-Marketing Surveillance Study

A significant clinical trial involving Desonide 0.05% cream and lotion was conducted in India. This 3-week, multicenter, open-label, non-comparative Phase IV trial enrolled 1789 patients from 229 centers across India between January and August 2003. The study aimed to evaluate the efficacy and safety of Desowen in treating mild to moderate steroid-responsive dermatoses.

  • Patient Outcomes: Of the 1789 patients, 1483 completed the treatment as per protocol. At the end of the therapy, 98.5% of the patients showed an improvement in their dermatitis from baseline. Notably, 91.4% of patients experienced a global improvement of greater than 50% in their disease, and 19% achieved complete clearance of all lesions[1][5].

  • Safety Profile: The study found no adverse effects associated with the use of Desonide cream or lotion. Both formulations were equally effective in reducing symptom severity scores, and no patients dropped out due to adverse drug events. This safety profile extends to infants under 1 year of age, making Desonide a safe option for this demographic[1][5].

Clinical Trial Results for Desonate Gel

In addition to the cream and lotion formulations, Desonide is also available as a gel, marketed as Desonate Gel. Clinical trials for Desonate Gel involved subjects with mild to moderate atopic dermatitis.

  • Treatment Success: The trials defined treatment success as achieving clear or almost clear on the Investigator’s Global Severity Score (IGSS) with at least a 2-point change from the baseline IGSS. The results showed that 44% and 28% of subjects in two separate trials achieved treatment success with Desonate Gel, compared to 14% and 6% with the vehicle control[4].

  • Adverse Events: Adverse events at the application site were minimal, with the most common being application site burning, rash, and pruritus. These events were not significantly higher than those observed in vehicle-treated subjects[4].

Market Analysis

Global Market Overview

The Desonide market is part of the broader topical corticosteroid market, which is segmented by type, application, and region.

  • Market Size and Growth: The global Desonide market size for 2023 was estimated to be significant, with a compound annual growth rate (CAGR) expected to drive growth from 2024 to 2031. The market is analyzed across major regions including North America, Europe, Asia Pacific, Middle East & Africa, and Latin America[2].

  • Regional Insights: The market analysis provides detailed insights into revenue share, current trends, and future prospects at the country and regional levels. This includes an understanding of key industry segments and their global, regional, and country-level insights[2].

Market Segmentation

The Desonide market is segmented based on type and application.

  • Type: The market includes various formulations such as creams, lotions, and gels. Each type has its own market share and growth prospects[2].

  • Application: Desonide is used in treating various steroid-responsive dermatoses, including atopic dermatitis, eczema, and other mild to moderate skin conditions. The demand for Desonide across different end-use industries is analyzed to understand market trends and opportunities[2].

Market Projections

Forecast Period

The market forecast for Desonide extends from 2024 to 2031, with the base year being 2023. This period will see significant growth driven by several factors.

  • Growth Drivers: The increasing prevalence of skin conditions, favorable regulatory scenarios, and advancements in dermatological treatments are expected to drive the market growth. Additionally, the growing awareness and demand for low-potency topical steroids like Desonide will contribute to the market expansion[2].

  • Regional Growth: The Asia Pacific region is expected to be a significant contributor to the growth of the Desonide market due to a large patient population and increasing healthcare expenditure. Other regions, such as North America and Europe, will also see substantial growth driven by advanced healthcare systems and higher adoption rates of topical corticosteroids[2].

Competitive Landscape

The Desonide market is competitive, with several pharmaceutical companies involved in the production and distribution of Desonide formulations.

  • Key Players: The market report includes an analysis of key competitors, their market share, and their strategies. This helps in understanding the competitive dynamics and potential future market leaders[2].

Regulatory and Technological Trends

Regulatory Support

Regulatory agencies play a crucial role in the growth of the Desonide market. Guidelines and recommendations from agencies like the FDA facilitate the adoption of new formulations and treatment approaches.

  • Decentralized Clinical Trials: The trend towards decentralized clinical trials, which includes the use of mobile healthcare, telemedicine, and wearable devices, is expected to enhance patient access and trial efficiency. This could lead to more robust clinical data and faster approval processes for new Desonide formulations[3].

Technological Advancements

Advancements in dermatological treatments and the development of new formulations are expected to drive the market forward.

  • Innovative Formulations: The development of new formulations such as gels, which offer better patient compliance and efficacy, will continue to influence market growth. Technological trends in drug delivery systems and the use of nanotechnology in topical corticosteroids are also expected to play a significant role[2].

Key Takeaways

  • Efficacy and Safety: Desonide 0.05% cream, lotion, and gel have been proven to be safe and effective in treating mild to moderate steroid-responsive dermatoses.
  • Market Growth: The global Desonide market is expected to grow significantly from 2024 to 2031, driven by increasing demand, favorable regulatory scenarios, and technological advancements.
  • Regional Insights: The Asia Pacific region is anticipated to be a major contributor to market growth, along with North America and Europe.
  • Competitive Landscape: The market is competitive, with several key players involved in the production and distribution of Desonide formulations.

FAQs

What is Desonide used for?

Desonide is used for the treatment of mild to moderate steroid-responsive dermatoses, including conditions such as atopic dermatitis and eczema.

What are the different formulations of Desonide?

Desonide is available in various formulations, including creams, lotions, and gels.

Is Desonide safe for infants?

Yes, Desonide has been found to be safe and effective in infants under 1 year of age[1][5].

What is the expected growth rate of the Desonide market?

The Desonide market is expected to grow at a significant CAGR from 2024 to 2031, driven by various market drivers[2].

Which regions are expected to contribute most to the growth of the Desonide market?

The Asia Pacific region, along with North America and Europe, is expected to be a major contributor to the growth of the Desonide market[2].

Sources

  1. Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: A post-marketing surveillance study. International Journal of Dermatology, Venereology and Leprology.
  2. Desonide Market Report 2024 (Global Edition). Cognitive Market Research.
  3. Decentralised Clinical Trials market is estimated to grow at a CAGR of 7.6% by 2034. Visiongain.
  4. Desonate™ (desonide) Gel 0.05% Rx Only. FDA.
  5. Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses. PubMed.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.